FIELD: medicine.
SUBSTANCE: patients are examined for the intracellular levels of cardiac protein troponin T (cTnT) or cardiac protein troponin I (cTnl) in the cardiac tissue. The values appearing to be reduced by min. 50% in relation to the control and normal values is a sign of the cardiac involvement in the patient. The method of treating involves detecting the patients with the cardiac involvement by the declared method and introducing the therapeutically effective amount of GGF2 and a proteasome inhibitor. The increasing intracellular levels of the protein cTnT or cTnl in the patient's cardiac tissue after GGF2 has been introduced, are a positive sign of the effective introduction of GGF2 for treating the patient with the cardiac involvement.
EFFECT: using the declared group of inventions enables fast and accurate diagnosis of the cardiac involvement in the patient, as well as fast and accurate estimation of the effectiveness of the conducted therapy.
19 cl, 26 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR ACHIEVING DESIRED GLIAL GROWTH FACTOR 2 PLASMA LEVELS | 2014 |
|
RU2687097C2 |
METHOD OF PROVIDING REQUIRED LEVELS OF GLIAL GROWTH FACTOR 2 IN PLASMA | 2009 |
|
RU2530650C2 |
FERRITIN NANOPARTICLES CONTAINING CHEMOTHERAPEUTIC AGENT | 2019 |
|
RU2810594C2 |
COMPOSITIONS AND METHODS FOR TREATING NON-ACUTE PERIODS FOLLOWING NEUROLOGICAL DAMAGE | 2009 |
|
RU2501564C2 |
COMPOSITIONS AND METHODS FOR TREATMENT DURING NON-ACUTE PERIODS FOLLOWING NEUROLOGICAL CNS DAMAGE | 2013 |
|
RU2646507C2 |
CELL AND GENE METHODS FOR IMPROVEMENT OF CARDIAC FUNCTION | 2012 |
|
RU2608957C2 |
METHOD FOR CARDIO-GENERATIVE POTENTIAL DETERMINATION IN MAMMAL CELLS | 2010 |
|
RU2624498C2 |
APPLICATION OF PEPTIDE GGF2 IN TREATMENT OR PREVENTION OF HEART FAILURE IN MAMMALS | 2009 |
|
RU2536938C2 |
THERAPEUTIC DOSING OF NEUREGULIN OR ITS SUB-SEQUENCE FOR TREATING OR PREVENTING HEART FAILURE | 2014 |
|
RU2698090C2 |
USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
Authors
Dates
2013-11-10—Published
2008-05-12—Filed